ZA959008B - Competitive progesterone antagonists for demand-oriented female birth control - Google Patents

Competitive progesterone antagonists for demand-oriented female birth control

Info

Publication number
ZA959008B
ZA959008B ZA959008A ZA959008A ZA959008B ZA 959008 B ZA959008 B ZA 959008B ZA 959008 A ZA959008 A ZA 959008A ZA 959008 A ZA959008 A ZA 959008A ZA 959008 B ZA959008 B ZA 959008B
Authority
ZA
South Africa
Prior art keywords
demand
birth control
progesterone antagonists
competitive progesterone
female birth
Prior art date
Application number
ZA959008A
Other languages
English (en)
Inventor
Kristoff Chwalisz
Klaus Stoeckemann
Karin Schmidt-Gollwitzer
Walter Klemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA959008B publication Critical patent/ZA959008B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
ZA959008A 1994-10-24 1995-10-24 Competitive progesterone antagonists for demand-oriented female birth control ZA959008B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4438820 1994-10-24

Publications (1)

Publication Number Publication Date
ZA959008B true ZA959008B (en) 1996-09-16

Family

ID=6532105

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959008A ZA959008B (en) 1994-10-24 1995-10-24 Competitive progesterone antagonists for demand-oriented female birth control

Country Status (25)

Country Link
US (1) US6143754A (fi)
EP (1) EP0787002B1 (fi)
JP (1) JPH10507461A (fi)
KR (1) KR970706827A (fi)
CN (1) CN1211087C (fi)
AT (1) ATE347894T1 (fi)
AU (1) AU707235B2 (fi)
BG (1) BG62877B1 (fi)
BR (1) BR9509478A (fi)
CA (1) CA2203541A1 (fi)
CZ (1) CZ290690B6 (fi)
DE (1) DE59511071D1 (fi)
DK (1) DK0787002T3 (fi)
ES (1) ES2279515T3 (fi)
FI (1) FI971742A (fi)
HU (1) HU226566B1 (fi)
IL (1) IL115738A (fi)
NO (1) NO314437B1 (fi)
NZ (1) NZ295365A (fi)
PL (1) PL319869A1 (fi)
PT (1) PT787002E (fi)
RO (1) RO120606B1 (fi)
SK (1) SK283662B6 (fi)
WO (1) WO1996012494A1 (fi)
ZA (1) ZA959008B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CO5200773A1 (es) * 1999-08-31 2002-09-27 Jenapharm Gmbh And Co Kg Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh)
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
SK2982002A3 (en) * 1999-08-31 2002-07-02 Jenapharm Gmbh Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
EP2234491A4 (en) * 2007-12-20 2010-12-22 Teva Womens Health Inc DOSAGE SCHEMES AND PHARMACEUTICAL COMPOSITIONS AND PACKAGING FOR EMERGENCY CONTRACEPTION
CA2758764C (en) * 2009-04-14 2017-04-11 Elizabeth Gray Raymond Method for on-demand contraception using levonorgestrel or norgestrel
ME02548B (me) 2009-04-14 2017-02-20 Hra Pharma Lab Postupak za kontracepciju po potrebi
JP6370887B2 (ja) 2013-05-23 2018-08-08 バイエル・ファルマ・アクティエンゲゼルシャフト オンデマンド避妊のための医薬組成物およびその使用、ならびにこの医薬組成物の適用体制
CA2966753A1 (en) * 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
WO2017053793A1 (en) 2015-09-25 2017-03-30 Arno Therapeutics, Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein

Also Published As

Publication number Publication date
KR970706827A (ko) 1997-12-01
US6143754A (en) 2000-11-07
DE59511071D1 (de) 2007-01-25
CZ118097A3 (en) 1997-07-16
RO120606B1 (ro) 2006-05-30
PT787002E (pt) 2007-03-30
DK0787002T3 (da) 2007-04-10
NZ295365A (en) 1999-07-29
AU707235B2 (en) 1999-07-08
HU226566B1 (en) 2009-04-28
FI971742A0 (fi) 1997-04-23
CN1211087C (zh) 2005-07-20
NO971869D0 (no) 1997-04-23
BG101427A (en) 1997-11-28
EP0787002A1 (de) 1997-08-06
CN1161649A (zh) 1997-10-08
FI971742A (fi) 1997-04-23
EP0787002B1 (de) 2006-12-13
ES2279515T3 (es) 2007-08-16
BG62877B1 (bg) 2000-10-31
JPH10507461A (ja) 1998-07-21
IL115738A0 (en) 1996-01-19
CA2203541A1 (en) 1996-05-02
MX9703018A (es) 1997-10-31
NO971869L (no) 1997-04-23
ATE347894T1 (de) 2007-01-15
AU3869695A (en) 1996-05-15
NO314437B1 (no) 2003-03-24
BR9509478A (pt) 1997-09-30
CZ290690B6 (cs) 2002-09-11
IL115738A (en) 2002-05-23
WO1996012494A1 (de) 1996-05-02
SK283662B6 (sk) 2003-11-04
HUT77518A (hu) 1998-05-28
PL319869A1 (en) 1997-09-01
SK51897A3 (en) 1997-09-10

Similar Documents

Publication Publication Date Title
IL115738A0 (en) Competitive progesterone antagonists
NZ234051A (en) Treating post-menopausal disorders using an estrogenic compound mixed with a compound having progestational activity
DK0735882T3 (da) Kombinationsprodukt til kontraception indeholdende progesteronantagonister og gestagen
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
ZA946142B (en) Therapeutic heterocycles
HU9602668D0 (en) Progesterone antagonists useful preparing medicaments for treating dysfunctional uterine bleeding
MX9702162A (es) Procedimiento para hacer unidades de dosis mediante granulacion en humedo.
NZ291417A (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
GB1459675A (en) Method for the prevention of conception
MY103741A (en) Process for producing an administration and/or dosage form for medicinal active substances by means of a printing process
HUP0102913A2 (hu) Biogén ösztrogén-szulfamátok alkalmazása hormonhelyettesítő terápiánál használható gyógyszerkészítmények előállítására
ATE59960T1 (de) Theophyllintabletten mit verzoegerter freigabe.
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
ES8802372A1 (es) Procedimiento para preparar un agente que contiene tirosina o un derivado de tirosina como sustancia activa para mejorar la fecundidad de mamiferos.
EP0301850A3 (en) Lhrh antagonist analogs and 19-nor-progestational steroids for therapy
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
HUP9900313A1 (hu) Antiösztrogének alkalmazása hím nemzőképesség szabályozására
Asbjorn et al. Low dose of gestagen as a contraceptive method. A clinical trial
PT1150683E (pt) Utilizacao de dienogest em doses elevadas
Robertson A study of women on the progestogen only pill
UA23364A (uk) Спосіб лікування гострого ендометриту